210 related articles for article (PubMed ID: 30605006)
1. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
[TBL] [Abstract][Full Text] [Related]
2. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
[TBL] [Abstract][Full Text] [Related]
3. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
[TBL] [Abstract][Full Text] [Related]
4. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
[TBL] [Abstract][Full Text] [Related]
5. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
6. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Gori A; Antinori A; Vergori A; Cossu MV; Menzaghi B; Sterrantino G; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):290-294. PubMed ID: 32101882
[TBL] [Abstract][Full Text] [Related]
8. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
10. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.
Echeverría P; Bonjoch A; Puig J; Ornella A; Clotet B; Negredo E
HIV Med; 2017 Nov; 18(10):782-786. PubMed ID: 28671337
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
12. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
13. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
[TBL] [Abstract][Full Text] [Related]
14. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
15. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the number of drugs in darunavir/cobicistat regimens.
Martinez E; Negredo E; Knobel H; Ocampo A; Sanz J; Garcia-Fraile L; Martin-Carbonero L; Lozano F; Gonzalez-Domenech CM; Gutierrez M; Montero M; Boix V; Payeras A; Torralba M; Gonzalez-Cordon A; Moreno A; Alejos B; Perez-Elias MJ;
J Antimicrob Chemother; 2020 Jan; 75(1):208-214. PubMed ID: 31586414
[TBL] [Abstract][Full Text] [Related]
17. Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
López-Ruz MA; López-Zúñiga MA; Gonzalvo MC; Sampedro A; Pasquau J; Hidalgo C; Rosario J; Castilla JA
PLoS One; 2018; 13(4):e0196257. PubMed ID: 29689065
[TBL] [Abstract][Full Text] [Related]
18. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
19. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
20. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
